Barely Significant
← all excerpts

Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia.

Haematologica · 2018 · PMC6068018 · PMID 29724902

Europe PMCDOI
1
hedged sentence
0.0221
closest p · 0.4× alpha
0.0221
boldest claim

The sentences

highly significantP =0.0221actually significant
The mobilizing effect of plerixafor was highly significant ( P =0.0221) among clinical responders (n=21) versus non-responders (n=19) ( Figure 4B ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.